CN Mobile Logo

Search form


Lung Cancer

Understanding the Links Between Lung Cancer, COPD, and Emphysema

A better delineation of the relationships these three entities may lead to significant improvements in the effectiveness of lung cancer screening programs, and to reductions in the morbidity and mortality associated with these deadly diseases.

Lung Cancer

Evidence suggests that the inclusion of ventilation in cigarette filters has contributed to the increased rate of lung adenocarcinoma among smokers.

Adjuvant gefitinib significantly prolonged time to recurrence compared with the standard of care for patients with NSCLC with EGFR-activating mutations.

The FDA has approval pembrolizumab (Keytruda), in combination with chemotherapy, for the first-line treatment of patients with metastatic non-squamous non–small-cell lung cancer.

Seasonal influenza vaccination resulted in increased risk of immune-related adverse events in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors, though risk of the flu itself may still outweigh the risks associated with vaccination.

Adding selumetinib to docetaxel does not provide any significant benefit over docetaxel alone for patients previously treated for advanced KRAS-mutant non–small-cell lung cancer.

Pretreatment with immune checkpoint inhibitors are associated with a higher likelihood of response to salvage chemotherapy in patients with advanced non–small-cell lung cancer.

The FDA has approved brigatinib (Alunbrig) for the treatment of metastatic ALK-positive non-small-cell lung cancer, specifically in patients who have progressed on or are intolerant to crizotinib.


Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.